Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
5(62.5%)
Phase 2
3(37.5%)
8Total
Phase 1(5)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT04382664Phase 2Completed

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Role: lead

NCT02275416Phase 1Completed

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

Role: lead

NCT01784913Phase 1Completed

A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer

Role: lead

NCT01789099Phase 1Completed

A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.

Role: lead

NCT03538314Phase 1Completed

UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma

Role: lead

NCT04701021Phase 1Completed

TENDU Vaccine in Patients With Relapse After Primary Radical Prostatectomy

Role: lead

NCT04300244Phase 2Active Not Recruiting

Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma

Role: collaborator

NCT05075122Phase 2Unknown

Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab

Role: collaborator

All 8 trials loaded